Pharmacyclics (4/10/13) âMajor Ibrutinib Competitor – ABT-199 – Still Seeing Tumor Lysis Syndrome; Richter’s Transformation Issues Completely Overblown. At the AACR, Rod Humerickhouse, M.D., Ph.D. of AbbVie presented an update on ABT-199, a Bcl-2 inhibitor, under development for hematologic malignancies similar to PCYC ibrutinib. Recall back in January, AbbVie suspended trials as two patients died from tumor lysis syndrome due (TLS) to[…]